The largest database of trusted experimental protocols

Conjugated to horseradish peroxidase

Manufactured by GE Healthcare
Sourced in United Kingdom

Conjugated to horseradish peroxidase is a type of lab equipment used for various analytical and diagnostic applications. This product is a conjugate, meaning it combines a specific target molecule with the enzyme horseradish peroxidase. The core function of this conjugate is to facilitate the detection and quantification of the target molecule through enzymatic reactions.

Automatically generated - may contain errors

5 protocols using conjugated to horseradish peroxidase

1

Western Blot Analysis of MAPK Signaling

Check if the same lab product or an alternative is used in the 5 most similar protocols
Cell lysates were prepared by the addition of sodium dodecyl sulfate (SDS) sample buffer (4% SDS (v/v), 0.1 M dithiothreitol, 20% glycerol (v/v), 0.0625 M Tris–HCl and 0.004% bromophenol blue (w/v) and heated for 10 min at 100°C. Protein was resolved on a 4–12% Novex Tris-glycine gel (Invitrogen Life Technologies, Paisley, UK) and transferred to Hybond-N membranes (GE Healthcare Life Sciences, Buckinghamshire, UK) using a Novex X-Cell II Mini Cell. Blots were reacted with rabbit antimouse total or phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (197G2, New England Biolabs, Herts, UK). Detection was subsequently performed with species-specific secondary antibodies conjugated to horseradish peroxidase (GE Healthcare Life Sciences). Protein loading was confirmed by antimouse β-actin antibody (eBioscience). Blots were visualised by enhanced chemiluminescence (GE Healthcare Life Sciences) and digital images and densitometry performed using a chemi-doc Bio-Rad system. Data were expressed as relative quantification normalised to β-actin expression and presented as fold change from unstimulated cells.
+ Open protocol
+ Expand
2

Western Blot Quantification of CD99

Check if the same lab product or an alternative is used in the 5 most similar protocols
Western blot experiments were performed according to standard protocols. Samples were lysed in radioimmunoprecipitation assay (RIPA) buffer (50 mm Tris-HCl, pH 7.4, 150 mm NaCl, 0.1% sodium dodecyl sulfate (SDS), 1% Triton X-100, 5 mm ethylenediaminetetraacetic acid (EDTA), 1% deoxycholate) supplemented with protease inhibitors.
Equivalent amounts of lysates were run on SDS gels under denaturing conditions and blotted onto nitrocellulose membranes. The membranes were incubated overnight with anti-CD99 (12E7; sc-53148; Santa Cruz Biotechnology, Santa Cruz, Dallas, USA), anti-GAPDH (sc-25778; Santa Cruz Biotechnology), anti-c-Fos (9F96; #2250; Cell Signaling Technology) primary antibodies. Anti-rabbit or anti-mouse antibodies conjugated to horseradish peroxidase (GE Healthcare, Little Chalfont, UK) were used as secondary antibodies. The proteins were visualized with an ECL Western Blotting Detection System (GE Healthcare). The signal for CD99 protein was quantified by using GS-800 imaging densitometer (Bio-Rad, Hercules, CA) and the Quantity One 4.6.9 software (Bio-Rad). The values are represented as optical Density (OD).
+ Open protocol
+ Expand
3

Protein Expression Analysis in Treated Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
Cells were treated with NT157 (0.3–1.3 μM) for 48 h or left untreated, and cell lysates were prepared and processed as previously described (30 (link)). The membranes were incubated overnight with the following primary antibodies: anti-Shc clone PG-797, anti GAPDH, anti-β-actin (Santa Cruz Biotechnology, San Diego, CA, USA), anti-phospho-Akt (Ser473) clone 736E11, anti-Akt, anti-ERK (Cell Signaling Technology, Beverly, MA, USA), anti-phospho-ERK (Tyr202/Tyr204) (Covance, Princeton, NJ, USA), anti-IRS-1 (Upstate Biotechnology, Temecula, CA, USA), anti-IRS-2 (Abcam, Cambridge, UK), and phospho-IRS-1 (Tyr612) (Invitrogen, USA); anti-rabbit or anti-mouse antibodies conjugated to horseradish peroxidase (GE Healthcare, Piscataway, NJ, USA) were used as secondary antibodies.
+ Open protocol
+ Expand
4

Evaluating TRaM and Rapamycin on mTOR Inhibition

Check if the same lab product or an alternative is used in the 5 most similar protocols
To assess the efficacy of TRaM and free rapamycin on inhibiting MCEC mTOR activity, MCECs were again exposed to simulated cold hypoxic reperfusion injury, using the model outlined above. In these experiments, UW solution was augmented with TRaM, empty micelles, free rapamycin, or DMSO vehicle. Following 6, 12, 18, 24, or 72 hours of reperfusion, MCEC protein lysates were collected and analyzed by western blot as previously described.14 (link) Briefly, cells were washed, detached mechanically, pelleted and lysed with M-PER Mammalian Protein Extraction Reagent (Thermo Fisher Scientific, MA) that contained 1× phosphatase and 1× protease cocktail inhibitors (Thermo Fisher Scientific, MA). After quantification, proteins were denatured and separated using 4–20% gradient SDS-PAGE (Bio-Rad Laboratories, CA), followed by wet transfer to a PVDF membrane (Bio-Rad Laboratories, CA) for immunoblotting. Primary antibodies against P-p70S6K (Thr389), p70S6K (all from Cell Signaling, MA), beta actin (Santa Cruz, TX) were used at a 1 : 1000 dilution. Secondary antibodies conjugated to horseradish peroxidase (GE Healthcare, Little Chalfont, UK) were used at a 1 : 2000 dilution. Signal was determined by chemiluminescence using film development and digital imaging methodologies. Quantification of band intensity was performed using ImageJ v1.46 (NIH, MD).
+ Open protocol
+ Expand
5

Modulation of Cell Signaling Pathways

Check if the same lab product or an alternative is used in the 5 most similar protocols
Unstimulated or stimulated T cell-enriched PBMCs were treated with different concentrations of BKM120 or BEZ235. After 48 h, cells were lysed and cell extracts were electrophoresed, transferred onto PVDF membrane (Millipore, Bedford, MA, USA), and immunoblotted with antibodies against caspase 3, phosphorylated AKT (p-AKT) (T308 and S473), total AKT, phosphorylated 4E-BP1 (p-4E-BP1) (T37/46), total 4E-BP1, phosphorylated RPS6 (p-RPS6) (S235/236), total RPS6, phosphorylated p38 MAPK (p-p38) (T180/Y182), total p38 MAPK, phosphorylated ERK1/2 (p-ERK1/2) (T202/Y204) (all from Cell Signaling Thechnology®, Leiden, Netherlands), or total ERK2 (Santa Cruz Biotechnology, Heidelberg, Germany); antibodies to GAPDH (Cell Signaling Thechnology®) and calnexin (Enzo® Life Science, Plymouth Meeting, PA, USA) were used as loading controls. Anti-rabbit or anti-mouse antibodies conjugated to horseradish peroxidase (GE Healthcare, Buckinghamshire, UK) were used as secondary antibodies. Proteins were visualized with an ECL detection system (GE Healthcare).
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!